GlassScriptPhysician profile
Stephen A Brunton
NPI 1134116957
$1,299,779.93
in general payments reported to CMS, 2019-2025
40 companies · $116K in 2025
The $116K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203K · 2020: $168K · 2021: $192K · 2022: $210K · 2023: $184K · 2024: $227K · 2025: $116K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $285K · Consulting Fee: $144K · Travel and Lodging: $64K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Food and Beverage: $15K · Honoraria: $1,800 · Education: $82.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $284,704.01 |
| Consulting Fee | $143,820.75 |
| Travel and Lodging | $63,894.24 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $16,812.50 |
| Food and Beverage | $14,892.10 |
| Honoraria | $1,800.00 |
| Education | $82.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $414,547.46 | 2019-2025 | Mounjaro, Trulicity, Amyvid |
| Novo Nordisk INC | $166,632.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $142,023.96 | 2019-2025 | Airsupra, Breztri, Flumist Quadrivalent |
| Astrazeneca Uk Limited | $73,668.76 | 2019-2025 | Airsupra, Farxiga |
| Acadia Pharmaceuticals INC | $71,343.59 | 2019-2021 | |
| Abbott Laboratories | $70,915.14 | 2019-2025 | Freestyle Libre 3, Freestyle Libre, Afinion Hba1c Dx |
| Bayer Healthcare Pharmaceuticals INC. | $67,536.39 | 2019-2025 | |
| Eli Lilly and Company | $60,749.83 | 2019-2025 | Jardiance, Kisunla |
| Phathom Pharmaceuticals, INC. | $54,403.53 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46,667.27 | 2019-2024 | Stiolto Respimat, Jardiance |
| Sanofi-Aventis U.S. LLC | $34,031.81 | 2019-2024 | |
| Astrazeneca Ab | $11,822.67 | 2019-2023 | |
| Astellas Pharma US INC | $11,255.59 | 2022-2023 | Veozah |
| Lifescan, INC. | $7,729.86 | 2022 | |
| Genentech USA, INC. | $7,613.87 | 2019 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $7,373.38 | 2022-2025 | Trelegy Ellipta |
| Aegerion Pharmaceuticals, INC. | $6,469.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $5,425.04 | 2022-2023 | Seglentis |
| Shield Therapeutics INC | $4,937.79 | 2022-2023 | Accrufer |
| Mylan INC. | $4,704.01 | 2019 | |
| Boehringer Ingelheim International Gmbh | $4,375.00 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $4,238.37 | 2019 | |
| F. Hoffmann-La Roche Ag | $4,050.00 | 2021 | |
| Insulet Corporation | $3,512.00 | 2025 | Omnipod |
| Genzyme Corporation | $2,625.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $2,500.00 | 2022 | |
| Ferring Pharmaceuticals As | $2,205.00 | 2025 | |
| Idorsia Pharmaceuticals US INC | $1,924.16 | 2024-2025 | Tryvio |
| Neurocrine Biosciences, INC. | $1,912.50 | 2020 | |
| Esperion Therapeutics, INC. | $939.58 | 2020-2023 | Nexletol |
| Xeris Pharmaceuticals, INC. | $849.00 | 2020 | |
| Dexcom, INC. | $404.39 | 2023-2025 | Dexcom G6 Transmitter |
| Renalytix Ai, INC. | $188.45 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma Global Development | $67.43 | 2024-2025 | Veozah |
| Amarin Pharma, INC. | $41.11 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $27.09 | 2023 | Onpattro |
| Alexion Pharmaceuticals, INC. | $20.64 | 2022 | |
| Corcept Therapeutics | $19.53 | 2024 | Korlym |
| Vital Connect, INC | $16.47 | 2022 | |
| Abbvie INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Brunton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.